CICC Initiates Coverage of Pfizer Inc. (PFE) With an Outperform Rating

robot
Abstract generation in progress

CICC has initiated coverage of Pfizer Inc. (PFE) with an Outperform rating and a $33 price target. This follows Pfizer’s announcement of positive topline results from its Phase 3 VALOR clinical trial for an investigational Lyme disease vaccine, showing over 70% efficacy with no safety concerns. The company plans to submit regulatory applications for the vaccine, highlighting its potential in an area with no currently available vaccines.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin